Qiagen: Shareholder Returns Proposals & Roche Diagnostics Day

Research evidence excerpt

Qiagen: Shareholder Returns Proposals & Roche Diagnostics Day

Deutsche Bank

Research

Rating Company Date

Buy Qiagen 12 May 2026

Breaking News

Europe

Germany

Reuters Bloomberg Exchange Ticker Price at 11 May 2026 (USD) 32.63

QGEN.N QGEN US NYS QGEN

Price Target (USD) 43.00

Healthcare

52-week range (USD) 55.66 - 32.63

Life Sciences Tools &

Diagnostics

Shareholder Returns Proposals & Roche

Valuation & Risks Diagnostics Day

Jan Koch, CFA

Summary takeaways Research Analyst

Qiagen has released its proposals for the upcoming 2026 Annual General Meeting +49-69-910-47428

(AGM) on June 24, 2026, which emphasize continued governance renewal and a

Falko Friedrichs

commitment to increased shareholder returns. The scale of the proposed share Research Analyst

repurchases constitutes a positive surprise and should be taken positively by the +49-69-910-36270

market.

Fynn Scherzler

Research Analyst

Key Points on higher Shareholder Returns

+49-69-910-40764

n New Synthetic Share Repurchase: The company is seeking shareholder Sachin Gadilingappa

approval for a new synthetic share repurchase of up to the currently allowed Research Associate

maximum of $200 million.

n Open-Market Share Repurchases: Shareholder authorization is also being

sought for additional open-market share repurchases of up to 10% of the

company's share capital.

n Dividend Increase: A 40% increase in the annual cash dividend is proposed,

raising it to $0.35 per share.

Other Key Proposals

n Supervisory Board Changes: Co-founder Dr. Metin Colpan will become

Honorary Chairman and Robert McMahon has been nominated for election

to the Supervisory Board as part of ongoing renewal.

n Managing Board: Thierry Bernard and Roland Sackers are proposed for re-

election to the Managing Board. Thierry Bernard will continue as CEO until